A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Part of paid clinical trials in Duarte, California.

Sponsor
Incyte Corporation
Study ID
NCT07195916
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Hematologic Malignancies
  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • INCA036873 — DRUG
    Intravenously (IV)

Study Details

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Key Dates

Start date
Jan 8, 2026
Status verified
Apr 2026
Primary completion
Aug 18, 2028
Completion
Aug 18, 2028

Study Design

Enrollment
280 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1a Dose Escalation
    INCA036873 will be administered at the protocol defined dose.
  • Experimental: Part 1b Dose Expansion
    INCA036873 will be administered at the protocol defined dose.
  • Experimental: Part 1c Pharmacodynamic Cohort
    INCA036873 will be administered at the protocol defined dose.

Primary Outcome Measure

Part 1A : Occurrence of Dose Limiting Toxicities (DLTs) [ Time Frame: Up to Day 28 ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
City of Hope Medical CenterDuarteCalifornia91010-
University of California San Diego Medical Center, Moores Cancer CenterLa JollaCalifornia92037-
University of MichiganAnn ArborMichigan48109-
The University of Nebraska Medical CenterOmahaNebraska68198-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10021-
Scri Oncology PartnersNashvilleTennessee37203-
Vanderbilt Medical CenterNashvilleTennessee37232-
Md Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Duarte, CA

By research site
City of Hope Medical Center· Duarte, CAUniversity of California San Diego Medical Center, Moores Cancer Center· La Jolla, CAUniversity of Michigan· Ann Arbor, MIThe University of Nebraska Medical Center· Omaha, NEMemorial Sloan Kettering Cancer Center· New York, NYScri Oncology Partners· Nashville, TN

Related Studies